Search

Your search keyword '"Scaldaferri, F."' showing total 157 results
Start Over Author "Scaldaferri, F." Publication Year Range Last 3 years
157 results on '"Scaldaferri, F."'

2. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

3. OC.07.9: ENDOSCOPIC BALLOON DILATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN'S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE

Author

Lopetuso, L.R., primary, Coppola, G., additional, Alfieri, N., additional, Morretta, C., additional, Di Vincenzo, F., additional, Puca, P., additional, Parisio, L., additional, Marmo, C., additional, Settanni, C.R., additional, Laterza, L., additional, Pugliese, D., additional, Riccioni, M.E., additional, Cammarota, G., additional, Papa, A., additional, Gasbarrini, A., additional, and Scaldaferri, F., additional

Published
2024
Full Text
View/download PDF

5. T.05.4: RENAL LITHOGENIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES CORRELATES WITH MICROBIOTA COMPOSITION, URINARY PROFILE AND DIETARY INTAKE

Author

Mignini, I., primary, Blasi, V., additional, Masucci, L., additional, De Maio, F., additional, Agrillo, C., additional, Monzo, F.R., additional, Laterza, L., additional, Settanni, C.R., additional, Scaldaferri, F., additional, Napolitano, D., additional, Schiavoni, E., additional, D'Amato, D., additional, De Ninno, G., additional, Baroni, S., additional, Garcovich, M., additional, Riccardi, L., additional, Grassi, F., additional, Cintoni, M., additional, Mele, M.C., additional, Gasbarrini, A., additional, Ferraro, P.M., additional, and Papa, A., additional

Published
2024
Full Text
View/download PDF

6. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

8. OC.07.8: THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

Author

Del Gaudio, A., primary, Parisio, L., additional, Cuccia, G., additional, Privitera, G., additional, Laterza, L., additional, Lopetuso, L.R., additional, Rumi, G., additional, De Biasio, F., additional, Mignini, I., additional, Coppola, G., additional, Gasbarrini, A., additional, Scaldaferri, F., additional, and Pugliese, D., additional

Published
2024
Full Text
View/download PDF

9. T.08.9: SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION

Author

Capobianco, I., primary, Graziani, C., additional, Del Chierico, F., additional, Puca, P., additional, Di Vincenzo, F., additional, Wlderk, G., additional, Pirro, M.A., additional, Putignani, L., additional, Laterza, L., additional, Bibbò, S., additional, Petito, V., additional, Lopetuso, L.R., additional, Gasbarrini, A., additional, and Scaldaferri, F., additional

Published
2024
Full Text
View/download PDF

10. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Author

Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., Scaldaferri F., Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., and Scaldaferri F.

Abstract

Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines. Results and conclusions Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.

Published
2023

11. P715 Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictors

Author

Privitera, G, primary, Parisio, L, additional, Perniola, S, additional, Varca, S, additional, Alivernini, S, additional, Tolusso, B, additional, Petito, V, additional, Napolitano, D, additional, Schiavoni, E, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, Armuzzi, A, additional, Gremese, E, additional, Guidi, L, additional, and Pugliese, D, additional

Published
2024
Full Text
View/download PDF

12. P363 Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn’s disease treated with ustekinumab

Author

Mignini, I, primary, Maresca, R, additional, Esposto, G, additional, Ainora, M E, additional, Liguori, A, additional, Cintoni, M, additional, Galasso, L, additional, Laterza, L, additional, Lopetuso, L R, additional, Garcovich, M, additional, Riccardi, L, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Zocco, M A, additional

Published
2024
Full Text
View/download PDF

14. P109 Organic Cation Transporter (OCTN)-1 variants shape innate immunity and predict individual response to vedolizumab In ulcerative colitis patients

Author

Capobianco, I, primary, Puca, P, additional, Masi, L, additional, Petito, V, additional, Pafundi, P C, additional, De Felice, M, additional, Fidaleo, M, additional, Di Vincenzo, F, additional, Del Chierico, F, additional, Delogu, G, additional, Palucci, I, additional, Laterza, L, additional, Pizzoferrato, M, additional, Schiavoni, E, additional, Napolitano, D, additional, Turchini, L, additional, Amatucci, V, additional, Strazzeri, M, additional, Pugliese, D, additional, Putignani, L, additional, Armuzzi, A, additional, Lopetuso, L R, additional, Gasbarrini, A, additional, Pani, G, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

16. P881 Real-life vs trial access to biologic therapy differences: a 2019-2020 experience in an Italian tertiary IBD center

Author

DI VINCENZO, F, primary, Maresca, R, additional, Mora, V, additional, Petito, V, additional, Turchini, L, additional, Amatucci, V, additional, Napolitano, D, additional, Schiavoni, E, additional, Lopetuso, L R, additional, Parisio, L, additional, Settanni, C R, additional, Pizzoferrato, M, additional, Armuzzi, A, additional, Pugliese, D, additional, Laterza, L, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

17. P750 Endoscopic balloon dilation associated with biological therapy in Crohn's Disease strictures: a single center experience

Author

Lopetuso, L R, primary, Coppola, G, additional, Alfieri, N, additional, Morretta, C, additional, Di Vincenzo, F, additional, Puca, P, additional, Parisio, L, additional, Marmo, C, additional, Settanni, C R, additional, Laterza, L, additional, Pugliese, D, additional, Riccioni, M E, additional, Cammarota, G, additional, Papa, A, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

18. N06 Self-care in patients affected by inflammatory bowel disease: SELF-IBD observational study in a single center

Author

Napolitano, D, primary, Schiavoni, E, additional, Amatucci, V, additional, Monaci, A, additional, Martella, P, additional, Orgiana, N, additional, Benini, V, additional, Di Massimo, A, additional, Turchini, L, additional, Giordano, L N, additional, Conticelli, C, additional, Pettinari, V, additional, De Vito, A, additional, Virone, C, additional, Lorusso, A, additional, Fanali, C, additional, Ribaudi, E, additional, Bernabei, T, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Cocchieri, A, additional

Published
2024
Full Text
View/download PDF

19. P460 The POCER index: application of a novel endoscopic score in a real-life cohort of patients with Crohn's disease after surgery

Author

Parisio, L, primary, Del Gaudio, A, additional, Privitera, G, additional, Cuccia, G, additional, Lopetuso, L R, additional, Laterza, L, additional, Rumi, G, additional, De Biasio, F, additional, Mignini, I, additional, Calvez, V, additional, Coppola, G, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Pugliese, D, additional

Published
2024
Full Text
View/download PDF

20. P1203 Fecal transplantation for Ulcerative Colitis from diet conditioned donors followed by dietary intervention results in favorable gut microbial profile and decreased gut inflammation compared to fecal transplantation alone

Author

Leibovitzh, H, primary, Sarbagili Shabat, C, additional, Hirsch, A, additional, Zittan, E, additional, Mentella, M C, additional, Petito, V, additional, Cohen, N A, additional, Ron, Y, additional, Fliss Isakov, N, additional, Pfeffer, J, additional, Yaakov, M, additional, Fanali, C, additional, Turchini, L, additional, Masucci, L, additional, Quaranta, G, additional, Kolonimos, N, additional, Godneva, A, additional, Weinberger, A, additional, Scaldaferri, F, additional, and Maharshak, N, additional

Published
2024
Full Text
View/download PDF

21. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study

Author

Mocci, G, primary, Scaldaferri, F, additional, Pugliese, D, additional, Savarino, E, additional, Bodini, G, additional, Cuomo, A, additional, Donnarumma, L, additional, Maconi, G, additional, Cataletti, G, additional, Rodino, S, additional, Sebkova, L, additional, Ferronato, A, additional, Gaiani, F, additional, Marzo, M, additional, Luppino, I, additional, Paese, P, additional, Elisei, W, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Napolitano, D, additional, Grossi, L, additional, Serio, M, additional, Scarcelli, A, additional, Lorenzetti, R, additional, Allegretta, L, additional, Rocco, G, additional, Zampaletta, C, additional, Bolognini, L, additional, Meucci, C, additional, Colucci, R, additional, Tonti, P, additional, Della Valle, N, additional, Piga, R, additional, Forti, G, additional, Onidi, F M, additional, Usai Satta, P, additional, Picchio, M, additional, Papa, A, additional, and Tursi, A, additional

Published
2024
Full Text
View/download PDF

22. P442 Renal lithogenic risk in patients with Inflammatory Bowel Diseases correlates with microbiota composition, urinary profile and dietary intake

Author

Mignini, I, primary, Blasi, V, additional, Masucci, L, additional, De Maio, F, additional, Agrillo, C, additional, Monzo, F R, additional, Laterza, L, additional, Scaldaferri, F, additional, Napolitano, D, additional, Schiavoni, E, additional, D' Amato, D, additional, De Ninno, G, additional, Baroni, S, additional, Mele, M C, additional, Grassi, F, additional, Cintoni, M, additional, Garcovich, M, additional, Riccardi, L, additional, Gasbarrini, A, additional, Ferraro, P M, additional, and Papa, A, additional

Published
2024
Full Text
View/download PDF

23. P1213 The effects of Escherichia coli Nissle 1917 on the gut microbiota composition in ulcerative colitis patients

Author

Puca, P, primary, Del Chierico, F, additional, Graziani, C, additional, Masi, L, additional, Coppola, G, additional, Di Vincenz, F, additional, Capobianco, I, additional, Lopetuso, L R, additional, Barbaro, M R, additional, Masucci, L, additional, Putignani, L, additional, Petito, V, additional, Marasco, G, additional, Sanguinetti, M, additional, Barbara, G, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

24. P908 Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)

Author

Noviello, D, primary, Savarino, E, additional, Fries, W, additional, Fantini, M C, additional, Conforti, F, additional, Orlando, A, additional, Ribaldone, D G, additional, Mocci, G, additional, Viganò, C, additional, Festa, S, additional, Spagnuolo, R, additional, Campigotto, M, additional, Grossi, L, additional, Gravina, A G, additional, Principi, M, additional, Imperatore, N, additional, Carvalhas, A, additional, Scardino, G, additional, Scaldaferri, F, additional, Ceccarelli, L, additional, Biancone, L, additional, Di Sario, A, additional, De Barba, C, additional, De Francesco, C, additional, Calderone, S, additional, Onali, S, additional, Vecchi, M, additional, Ventimiglia, M, additional, and Caprioli, F, additional

Published
2024
Full Text
View/download PDF

25. P096 Human extrachromosomal circular DNA is an emerging biomarker in Inflammatory Bowel Disease

Author

Petito, V, primary, DI VINCENZO, F, additional, Gerovska, D, additional, Piazzesi, A, additional, Russo, A, additional, Turchini, L, additional, Masi, L, additional, Lopetuso, L R, additional, Abreu, M T, additional, Regenberg, B, additional, Gasbarrini, A, additional, Putignani, L, additional, Bravo Araúzo, M J, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

26. P831 Acute infusion reactions due to different biologic agents in a large cohort of patients with Inflammatory Bowel Disease

Author

Colantuono, S, primary, Caruso, C, additional, Rumi, G, additional, Capobianco, I, additional, Blasi, V, additional, Termite, F, additional, Coppola, G, additional, Laterza, L, additional, Lopetuso, L R, additional, Mignini, I, additional, Napolitano, D, additional, Parisio, L, additional, Pugliese, D, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, and Papa, A, additional

Published
2024
Full Text
View/download PDF

27. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

28. Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

Author

Caruso, Cristiano, Laterza, Lucrezia, Settanni, Carlo Romano, Colantuono, S., Di Mario, Clara, Tolusso, Barbara, Castri, Federica, Gremese, Elisa, Scaldaferri, Franco, Armuzzi, Alessandro, De Simone, Clara, Peris, Ketty, Chiricozzi, Andrea, Gasbarrini, Antonio, Caruso C., Laterza L., Settanni C. R., Di Mario C., Tolusso B. (ORCID:0000-0002-9108-6609), Castri F., Gremese E. (ORCID:0000-0002-2248-1058), Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Gasbarrini A. (ORCID:0000-0002-7278-4823), Caruso, Cristiano, Laterza, Lucrezia, Settanni, Carlo Romano, Colantuono, S., Di Mario, Clara, Tolusso, Barbara, Castri, Federica, Gremese, Elisa, Scaldaferri, Franco, Armuzzi, Alessandro, De Simone, Clara, Peris, Ketty, Chiricozzi, Andrea, Gasbarrini, Antonio, Caruso C., Laterza L., Settanni C. R., Di Mario C., Tolusso B. (ORCID:0000-0002-9108-6609), Castri F., Gremese E. (ORCID:0000-0002-2248-1058), Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

We described a case of IPEX syndrome successfully controlled with dupilumab, an anti-IL4 receptor alpha subunit inhibitor. IPEX syndrome is a rare and generally fatal genetic disorder characterized by immune dysregulation, polyendocrinopathy and enteropathy, mostly diagnosed in early childhood. Nonetheless, cases reported in the last 20 years demonstrated that IPEX clinical spectrum encompasses more than the classical triad of early-onset intractable diarrhea, type 1 diabetes and eczema. Atypical cases of IPEX include patients with late-onset of symptoms, single-organ involvement, mild disease phenotypes or rare clinical features. A 21-year-old caucasian man presented with immune dysregulation (hypereosinophilia and elevated IgE), protein-losing enteropathy, polyendocrinopathy (thyroiditis, osteoporosis, delayed puberty), weight loss, eczema manifestations and celiac disease. IPEX syndrome was diagnosed because of the presence of a hemizygous mutation in FOXP3 gene (c.543C>T (p.S181S) in the exon 5). During the course of the disease, the patient developed erosive proctitis, pyoderma gangrenosum, and erythema nodosum. Symptoms improved only after enteral and parenteral corticosteroid therapy and the patient soon developed steroid-dependence. Notwithstanding various therapies including azathioprine, sirolimus, tacrolimus, adalimumab, vedolizumab, the patient failed to achieve a good control of symptoms without steroids. Almost exclusive enteral nutrition with a hypoallergenic, milk-protein free, amino acid-based food for special medical purposes. He continued to lose weight (BMI 14.5 kg/m2) with a consequent high limitation of physical activity and a progressive worsening of the quality of life. In consideration of the poor response to conventional immunosuppressants and the presence of type 2 inflammatory manifestations, treatment with dupilumab at an initial dose of 600 mg, followed by a maintenance dose of 300 mg every other week, according to atopic dermatitis

Published
2023

31. OC.04.3 REAL-LIFE VS TRIAL ACCESS TO BIOLOGIC THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Author

Laterza, L., primary, Di Vincenzo, F., additional, Maresca, R., additional, Russo, M.C., additional, Mora, V., additional, Petito, V., additional, Turchini, L., additional, Amatucci, V., additional, Napolitano, D., additional, Schiavoni, E., additional, Settanni, C., additional, Parisio, L., additional, Pizzoferrato, M., additional, Lopetuso, L., additional, Armuzzi, A., additional, Gasbarrini, A., additional, Pugliese, D., additional, and Scaldaferri, F., additional

Published
2023
Full Text
View/download PDF

32. T.06.8 REAL WORD LONG-TERM EFFICACY AND SAFETY OF VEDOLIZUMAB IN MANAGING ULCERATIVE COLITIS VERSUS CROHN'S DISEASE: RESULTS FROM “LONG VEDO” ITALIAN MULTICENTER STUDY

Author

Mocci, G., primary, Maconi, G., additional, Cataletti, G., additional, Mantia, B., additional, Serio, M., additional, Scarcelli, A., additional, Onidi, F.M., additional, Pagnini, C., additional, Graziani, M., additional, Di Paolo, M., additional, Pranzo, G., additional, Luppino, I., additional, Paese, P., additional, Monterubbianesi, R., additional, Faggiani, R., additional, Ferronato, A., additional, Perini, B., additional, Savarino, E., additional, Binaghi, L., additional, Schiavoni, E., additional, Napolitano, D., additional, Scaldaferri, F., additional, Papa, A., additional, Lorenzetti, R., additional, Pica, R., additional, Cocco, A., additional, Rodino, S., additional, Sebkova, L., additional, Zampaletta, C., additional, Gaiani, F., additional, Fanigliulo, L., additional, Allegretta, L., additional, Cuomo, A., additional, Donnarumma, L., additional, Della Valle, N., additional, Forti, G., additional, Dore, M., additional, Antonelli, E., additional, Bassotti, G., additional, Iannelli, C., additional, Aragona, G., additional, Lauria, A., additional, Piergallini, S., additional, Colucci, R., additional, Meucci, C., additional, Usai Satta, P., additional, Elisai, W., additional, and Tursi, A., additional

Published
2023
Full Text
View/download PDF

36. P828 Incidence and predictors of arterial and venous thromboembolic events in hospitalized patients with inflammatory bowel disease compared to patients with acute infective gastroenteritis and colitis: a propensity score-matched study

Author

Papa, A, primary, Lopetuso, L R, additional, Mignini, I, additional, Settanni, C R, additional, Scaldaferri, F, additional, Pugliese, D, additional, Laterza, L, additional, Covino, M, additional, Franceschi, F, additional, and Gasbarrini, A, additional

Published
2023
Full Text
View/download PDF

38. P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study

Author

Mocci, G, primary, Maconi, G, additional, Onidi, F M, additional, Cataletti, G, additional, Elisei, W, additional, Scaldaferri, F, additional, Lorenzetti, R, additional, Pagnini, C, additional, Scarcelli, A, additional, Graziani, M G, additional, Di Paolo, M C, additional, Pranzo, G, additional, Luppino, I, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Ferronato, A, additional, Savarino, E, additional, Pica, R, additional, Cocco, A, additional, Rodino, S, additional, Sebkova, L, additional, Zampaletta, C, additional, Gaiani, F, additional, Fanigliulo, L, additional, Allegretta, L, additional, Cuomo, A, additional, Donnarumma, L, additional, Della Valle, N, additional, Forti, G, additional, Antonelli, E, additional, Bassotti, G, additional, Iannelli, C, additional, Aragona, G, additional, Lauria, A, additional, Piergallini, S, additional, Colucci, R, additional, Binaghi, L, additional, Meucci, C, additional, Papa, A, additional, and Tursi, A, additional

Published
2023
Full Text
View/download PDF

39. N14 The satisfaction of IBD patients’ nursing care in biological therapy. Observational study

Author

Napolitano, D, primary, Cocchieri, A, additional, Orgiana, N, additional, Fanali, C, additional, Poscia, A, additional, Schiavoni, E, additional, Bernabei, T, additional, Amatucci, V, additional, Turchini, L, additional, Durini, E, additional, Strazzeri, M, additional, Laterza, L, additional, Lopetuso, L R, additional, Mora, V, additional, Papa, A, additional, Pugliese, D, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2023
Full Text
View/download PDF

40. N04 How to manage the concerns of patients with inflammatory bowel disease due to the transition from in-hospital to home management with oral or subcutaneous therapies: results of a survey of a cohort of patients in intravenous biologic treatment

Author

Napolitano, D, primary, Settanni, C R, additional, Parisio, L, additional, Schiavoni, E, additional, Pugliese, D, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, and Papa, A, additional

Published
2023
Full Text
View/download PDF

41. Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

Author

Caruso, C., primary, Laterza, L., additional, Settanni, C. R., additional, Colantuono, S., additional, Di Mario, C., additional, Tolusso, B., additional, Castrì, F., additional, Gremese, E., additional, Scaldaferri, F., additional, Armuzzi, A., additional, De Simone, C., additional, Peris, K., additional, Chiricozzi, A., additional, and Gasbarrini, A., additional

Published
2023
Full Text
View/download PDF

43. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

47. OC.10.6 THE ROLE OF OCTN1 IN PREDICTING INDIVIDUAL RESPONSE TO THERAPY IN ULCERATIVE COLITIS: TOWARDS A PERSONALIZED APPROACH

Author

Puca, P., primary, Masi, L., additional, Petito, V., additional, Magrì, C., additional, Fidaleo, M., additional, Del Chierico, F., additional, Palucci, I., additional, Lopetuso, L.R., additional, Laterza, L., additional, Settanni, C., additional, Schiavoni, E., additional, Napolitano, D., additional, Turchini, L., additional, Amatucci, V., additional, Strazzeri, M., additional, Bibbò, S., additional, Pugliese, D., additional, Armuzzi, A., additional, Gasbarrini, A., additional, and Scaldaferri, F., additional

Published
2022
Full Text
View/download PDF

48. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE

Author

Masi, L., primary, Petito, V., additional, Magrì, C., additional, Puca, P., additional, Fidaleo, M., additional, Palucci, I., additional, Del Chierico, F., additional, Ivagnes, V., additional, Mercuri, A., additional, Graziani, C., additional, Lopetuso, L.R., additional, Armuzzi, A., additional, Gasbarrini, A., additional, Pani, G., additional, and Scaldaferri, F., additional

Published
2022
Full Text
View/download PDF

49. Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre

Author

Napolitano, Daniele, Cioffi, F., Marocchini, G., Bernabei, T., Leonetti, Arianna, Fanali, Caterina, Orgiana, N., Amatucci, V., Gasbarrini, Antonio, Ratto, Carlo, Litta, Francesco, Scaldaferri, Franco, Napolitano D., Cioffi F., Marocchini G., Bernabei T., Leonetti A. (ORCID:0000-0001-9163-417X), Fanali C., Orgiana N., Amatucci V., Gasbarrini A. (ORCID:0000-0002-7278-4823), Ratto C. (ORCID:0000-0002-0556-0037), Litta F., Scaldaferri F. (ORCID:0000-0001-8334-7541), Napolitano, Daniele, Cioffi, F., Marocchini, G., Bernabei, T., Leonetti, Arianna, Fanali, Caterina, Orgiana, N., Amatucci, V., Gasbarrini, Antonio, Ratto, Carlo, Litta, Francesco, Scaldaferri, Franco, Napolitano D., Cioffi F., Marocchini G., Bernabei T., Leonetti A. (ORCID:0000-0001-9163-417X), Fanali C., Orgiana N., Amatucci V., Gasbarrini A. (ORCID:0000-0002-7278-4823), Ratto C. (ORCID:0000-0002-0556-0037), Litta F., and Scaldaferri F. (ORCID:0000-0001-8334-7541)

Abstract

Background: Patients with Crohn s disease can develop anal and perianal lesions, such as fistulas, ulcers, skin tags, perianal abscesses and strictures. Perianal Crohn s disease (PCD) is a condition that has a major impact on patients quality of life. The multidisciplinary team includes a nurse who manages the patient according to evidence-based medicine. Clinical practice and post-registration training are the way forward for nurses to acquire the skills needed to deliver quality care. Aims: This study explored the assessment of nurses knowledge of PCD. A cross-sectional survey was used to look at the nurses knowledge. Methods: The questionnaire was administered over 2 months, between September and October 2019. The questionnaire was anonymous, validated by a panel of experts in the field and consisted of 30 questions to assess knowledge and two questions to assess the need for training. It was directed to 120 clinical nurses in the departments of medicine and abdominal surgery. Results: There were 120 nurses enrolled, and 64.2% of nurses had cared for patients with PCD at least once. The survey showed a fairly low level of knowledge of the diagnostic and therapeutic care pathways for patients affected by PCD. On the other hand, a high need for training and in-depth study of the subject emerged. Conclusion: The nurse, an integral part of the multidisciplinary team, plays an important role in the education of these patients. Nurses present level of knowledge can certainly be improved thanks to their willingness to undertake training courses or to use information tools.

Published
2022

50. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial

Author

Shabat, C. S., Scaldaferri, Franco, Zittan, E., Hirsch, A., Mentella, Maria Chiara, Musca, Tania, Cohen, N. A., Ron, Y., Isakov, N. F., Pfeffer, J., Yaakov, M., Fanali, Chiara, Turchini, Laura, Masucci, Luca, Quaranta, Gianluca, Kolonimos, N., Godneva, A., Weinberger, A., Kopylov, U., Levine, A., Maharshak, N., Scaldaferri F. (ORCID:0000-0001-8334-7541), Mentella M. C. (ORCID:0000-0003-4552-3932), Musca T., Fanali C., Turchini L., Masucci L. (ORCID:0000-0002-8358-6726), Quaranta G., Shabat, C. S., Scaldaferri, Franco, Zittan, E., Hirsch, A., Mentella, Maria Chiara, Musca, Tania, Cohen, N. A., Ron, Y., Isakov, N. F., Pfeffer, J., Yaakov, M., Fanali, Chiara, Turchini, Laura, Masucci, Luca, Quaranta, Gianluca, Kolonimos, N., Godneva, A., Weinberger, A., Kopylov, U., Levine, A., Maharshak, N., Scaldaferri F. (ORCID:0000-0001-8334-7541), Mentella M. C. (ORCID:0000-0003-4552-3932), Musca T., Fanali C., Turchini L., Masucci L. (ORCID:0000-0002-8358-6726), and Quaranta G.

Abstract

Background: We evaluated whether integration of novel diets for donors and patients, in addition to faecal transplantation [FT], could increase FT remission rate in refractory ulcerative colitis [UC]. Methods: This was a blinded, randomised, controlled trial in adults with active UC, defined by a simple clinical colitis activity index [SCCAI] of ≥5 and ≤11 and endoscopic Mayo score 2-3, refractory to medication. Group 1 received free diet and single donor standard FT by colonoscopy on Day 1and rectal enemas on Days 2 and 14 without dietary conditioning of the donor. Group 2 received FT as above but with dietary pre-conditioning of the donor for 14 days and a UC Exclusion Diet [UCED] for the patients. Group 3 received the UCED alone. The primary endpoint was Week 8 clinical steroid-free remission, defined as SCCAI <3. Results: Of 96 planned patients, 62 were enrolled. Remission Week 8 Group 1 was 2/17 [11.8%], Group 2 was 4/19 [21.1%], Group 3 was 6/15 [40%] [non-significant]. Endoscopic remission Group 1 was 2/17 [12%], Group 2 was 3/19 [16%], Group 3 was 4/15 [27%] [Group 1 vs 3 p = 0.38]. Mucosal healing [Mayo 0] was achieved only in Group 3 [3/15, 20%] vs 0/36 FT patients [p = 0.022]. Exacerbation of disease occurred in 3/17 [17.6%] of Group 1, 4/19 [21.1%] of Group 2, and 1/15 [6.7%] of Group 3 [Group 2 vs 3, p = 0.35]. Conclusions: UCED alone appeared to achieve higher clinical remission and mucosal healing than single donor FT with or without diet. The study was stopped for futility by a safety monitoring board.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results